NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) Covered Calls
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing oral therapies for patients at high risk of cardiovascular disease. The firm is advancing its lead candidate, obicetrapib, a novel, once-daily CETP inhibitor designed to lower LDL cholesterol. By providing a convenient, effective oral treatment as an adjunct to statin therapy, the company aims to address significant unmet needs for patients struggling to reach therapeutic lipid goals.
You can sell covered calls on NewAmsterdam Pharma Company N.V. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NAMS (prices last updated Fri 4:16 PM ET):
| NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 29.86 | -0.28 | 28.00 | 38.00 | 1.0M | - | 3.5 |
| Covered Calls For NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 30 | 0.25 | 37.75 | -20.5% | -498.8% | |
| Apr 17 | 30 | 1.10 | 36.90 | -18.7% | -158.7% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
NewAmsterdam Pharma operates as a specialized biopharmaceutical entity centered on cardiovascular health. Its business model is built around the clinical development and potential commercialization of obicetrapib, a small-molecule CETP inhibitor. The company aims to position this therapy as a powerful, convenient oral treatment for patients with elevated LDL-cholesterol who remain at high risk for cardiovascular events despite the use of existing therapies, such as statins.
The company emphasizes high-impact research to fill gaps in the current treatment paradigm for dyslipidemia. Its approach involves rigorous clinical trial programs aimed at demonstrating both the safety and efficacy of its product candidates in diverse patient populations. By focusing on a single, highly promising mechanism of action, the firm seeks to bring a differentiated solution to a global market that remains significantly impacted by cardiovascular disease.
Competition
The cardiovascular and lipid-management market is highly competitive, featuring both established pharmaceutical giants and innovative biotechnology firms. NewAmsterdam Pharma faces rivalry from companies developing various LDL-lowering agents, including PCSK9 inhibitors and other emerging therapies. Key publicly traded, optionable competitors include Amgen, Regeneron Pharmaceuticals, and Novartis.
Strategic Outlook and Innovation
The firm remains focused on the successful execution of its ongoing late-stage clinical programs. A core strategic priority is the achievement of key regulatory milestones and the eventual preparation for commercial launch in major geographic markets. The company leverages an asset-light, capital-efficient development strategy, relying on deep expertise in cardiovascular medicine and strategic partnerships to advance its pipeline through the complex regulatory landscape.
Innovation is centered on clinical trial design and the generation of robust data sets that can support broad therapeutic labeling and clinical adoption. By focusing on patients who are inadequately managed by current standard-of-care treatments, the firm seeks to establish a meaningful market position. Through disciplined clinical development and a commitment to addressing persistent health challenges, the firm aims to create long-term value for patients and stakeholders.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | MRVL covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | REPL covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | QURE covered calls | |
| 5. | IBIT covered calls | 10. | SOFI covered calls | 5. | PATH covered calls | |
Want more examples? NAK Covered Calls | NANR Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
